Search research articles
Contact Us
Filters
Showing results (141-150 of 147) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 147 results.
Pediatric Blood & Cancer
|
September 12, 2022
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center
Monica L Hulbert, Deepa Manwani, Emily Riehm Meier, et al.
Haematologica
|
April 16, 2026
Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study
Talya Wittmann Dayagi, Laura Willis, Staci D Arnold, et al.
The Lancet. Haematology
|
February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial
Maria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
The Lancet. Haematology
|
August 25, 2022
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
Ali T Taher, Maria Domenica Cappellini, Antonis Kattamis, et al.
The Journal of Clinical Investigation
|
July 19, 2013
β-globin gene transfer to human bone marrow for sickle cell disease
Zulema Romero, Fabrizia Urbinati, Sabine Geiger, et al.
Haematologica
|
April 6, 2019
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
Zora R Rogers, Taizo A Nakano, Timothy S Olson, et al.
Annals of the American Thoracic Society
|
August 31, 2019
Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report
A Parker Ruhl, S Christy Sadreameli, Julian L Allen, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 147) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 147 results.
Pediatric Blood & Cancer
|
September 12, 2022
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center
Monica L Hulbert, Deepa Manwani, Emily Riehm Meier, et al.
Haematologica
|
April 16, 2026
Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study
Talya Wittmann Dayagi, Laura Willis, Staci D Arnold, et al.
The Lancet. Haematology
|
February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial
Maria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
The Lancet. Haematology
|
August 25, 2022
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
Ali T Taher, Maria Domenica Cappellini, Antonis Kattamis, et al.
The Journal of Clinical Investigation
|
July 19, 2013
β-globin gene transfer to human bone marrow for sickle cell disease
Zulema Romero, Fabrizia Urbinati, Sabine Geiger, et al.
Haematologica
|
April 6, 2019
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
Zora R Rogers, Taizo A Nakano, Timothy S Olson, et al.
Annals of the American Thoracic Society
|
August 31, 2019
Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report
A Parker Ruhl, S Christy Sadreameli, Julian L Allen, et al.
Page
of 15